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ABSTRACT
Acquired or de novo resistance to trastuzumab remains a barrier to patient 
survival and mechanisms underlying this still remain unclear. Using stable isotope 
labelling by amino acids in cell culture (SILAC)-based quantitative proteomics to 
compare proteome profiles between trastuzumab sensitive/resistant cells, we 
identified autophagy related protein 9A (ATG9A) as a down-regulated protein in 
trastuzumab resistant cells (BT474-TR). Interestingly, ATG9A ectopic expression 
markedly decreased the proliferative ability of BT474-TR cells but not that of the 
parental line (BT474). This was accompanied by a reduction of Her2 protein levels and 
AKT phosphorylation (S473), as well as a decrease in Her2 stability, which was also 
observed in JIMT1 and MDA-453, naturally trastuzumab-resistant cells. In addition, 
ATG9A indirectly promoted c-Cbl recruitment to Her2 on T1112, a known c-Cbl docking 
site, leading to increased K63 Her2 polyubiquitination. Whereas silencing c-Cbl 
abrogated ATG9A repressive effects on Her2 and downstream PI3K/AKT signaling, its 
depletion restored BT474-TR proliferative rate. Taken together, our findings show for 
this first time that ATG9A loss in trastuzumab resistant cells allowed Her2 to escape 
from lysosomal targeted degradation through K63 poly-ubiquitination via c-Cbl. This 
study identifies ATG9A as a potentially druggable target to overcome resistance to 
anti-Her2 blockade. 
INTRODUCTION
Approximately 20–25% of breast cancers 
(BCa) have amplification/overexpression of human 
epidermal growth factor receptor 2 (ErbB2/Her2), a 
member of receptor tyrosine kinase family [1]. Homo 
or dimerisation with other family members such as Her3 
results in phosphorylation of tyrosine residues within the 
cytoplasmic domain of the receptors and initiates signal 
transduction via the oncogenic PI3K/AKT and RAS/
MAPK pathways [2, 3]. Therapeutic targeting of ErbB 
family members for cancer therapy includes tyrosine kinase 
inhibitors (TKIs) or recombinant monoclonal antibodies 
such as Trastuzumab (Tst). Binding of trastuzumab to the 
extracellular domain of HER2 inhibits the downstream 
signaling and improves survival in patients within both the 
metastatic and adjuvant settings in BCa [4–6]. However, 
despite initial clinical benefits, patients frequently relapse 
after therapy or display primary resistance to trastuzumab-
based therapy indicating the presence de novo or acquired 
resistance [7, 8]. A number of mechanisms have been 
described to date, including hyperactivation of PI3K/
AKT pathway [9], heterodimerization with other family 
members or compassion through an alternate receptor 
pathway [10], co-expression of the truncated p95Her2 
receptor or loss Her2 expression [11]. Targeting these 
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mechanisms have however proven to be insufficient to 
block progression of disease indicating a critical demand 
to prevent treatment failure. 
Previously, autophagy has been indicated to play an 
important role in trastuzumab sensitivity in Her2 amplified 
breast cancer [12–14]. For instance, autophagy has been 
proposed to protect breast cancer cells from growth-
inhibitory effects of trastuzumab [15] and autophagy 
blockage restored trastuzumab sensitivity in trastuzumab 
resistant cells [13]. However, the contribution of specific 
members of autophagy related protein family in the 
development of trastuzumab resistance and whether their 
functions are through autophagy signaling remain poorly 
understood. Autophagy related protein 9A (ATG9A) is the 
only known multi-pass transmembrane autophagy protein 
among over 30 ATG proteins identified to date. It has six 
conserved transmembrane domains and cytosolic N- and 
C-termini that are non-homologous between mammals and 
yeast. The ATG9A trafficking pathway remains unclear; to 
date ULK1, ATG13 and p38-interacting protein (p38IP) 
have been shown to interact with ATG9A. Under basal 
conditions, ATG9A is found in the trans-Golgi network, 
recycling and late endosomes whereas upon autophagy 
induction it reallocates to the periphery of the cell and co-
localises with phagophore markers and autophagosomes. 
However, the function of ATG9A and its associated signaling 
in trastuzumab sensitivity in breast cancer were unknown. 
In this study, we performed a quantitative proteomic 
analysis followed by mass spectrometry in established 
trastuzumab sensitive and resistant Her2 amplified 
breast cancer cells. Our results revealed that ATG9A 
protein levels are markedly reduced in trastuzumab 
resistant cells and restoring ATG9A levels can decrease 
Her2 stability and its protein levels. Strikingly, in 
trastuzumab resistant cells, ATG9A acts independently 
of autophagy; overexpression of ATG9A resultedd in 
targeted endosomal/lysosomal degradation of Her2 and 
consequently a decrease in resistance to trastuzumab. 
Our results are indicative of a unique role of ATG9A 
in trastuzumab resistant cells and suggest a potential 
significance of ATG9A as a target in patients when Her2 
targeting drugs are no longer effective.
RESULTS 
SILAC analysis reveals ATG9A as a potential 
regulator of trastuzumab resistance
To identify the differentially modulated proteome 
involved in trastuzumab resistance, we performed a 
quantitative proteomic analysis using metabolic labelling 
by SILAC and followed by LC-MS/MS. Firstly, BT474 
parental and BT474-derived trastuzumab resistant cells 
(BT474-TR) were cultured in the presence of increasing 
amounts of trastuzumab to assess their proliferative 
response to the drug. Comparing to BT474 parental cells, 
BT474-TR cells did not respond to trastuzumab confirming 
the acquired resistance to the anti-Her2 monoclonal 
antibody (Figure 1A). Subsequently, parental BT474 and 
BT474 trastuzumab resistant (BT474-TR) cells were then 
grown for 7 cell divisions in R6K4 ‘medium’ or R10K8 
‘heavy’ medium, respectively. Lysates obtained from three 
independent experiments for each condition were mixed 
in order to decrease experimental error and increase 
biological significance (Figure 1B). A total of 5622 
unique proteins were identified (Figure 1C, Supplementary 
Table S1), among which we identified 328 significantly up-
regulated proteins in BT474 cells and 235 down-regulated 
in comparison with BT474-TR cells (Figure 1D). One of 
the most differentially dysregulated was ATG9A showing 
a pronounced down-regulation in parental BT474-TR cells 
(Log2 = 4.7864, sig.B 4.18E-18) and further validated by 
western blot (Figure 1E). GO analysis highlighted a variety 
of biological functions that ATG9a is mainly involved in, 
including autophagy and endosome regulation which our 
present study is focused on (Figure 1F). We then integrated 
our proteomic data with the STRING database. Of note, 
in agreement with previous studies, our analysis showed 
that whereas ATG9A was down-regulated, numerous 
central regulators of autophagy flux such MAP1LC3B 
(LC-3B), ULK1, ATG7, ATG3 and NF-KB, were up-
regulated in BT474-TR. In addition, SQSTM1 a negative 
marker for autophagy induction was reduced in BT474-TR 
(Figure 1G). Further analysis also confirmed RAB7A and 
LAMP1 presence in endosome/late endosome compartment 
and suggested a possible interaction between ATG9A and 
RAB7A, which might be important for endo-lysosomal 
trafficking of receptor tyrosine kinases (Figure 1G).
To establish the relevance of ATG9A expression 
levels with clinical outcome in breast cancer, we then 
utilized the online survival analysis tool KM Plotter, which 
integrates massive gene expression data and survival 
information derived from more than 3,000 patients from 
databases including The Cancer Genome Atlas (TCGA) 
[16]. The correlations of ATG9A expression levels with 
relapse free survival (RFS) in all breast cancer patients as 
well as in the subgroup of Her2 amplified breast cancer 
were assessed. Our analysis showed that high ATG9A 
levels were associated with longer RFS in all breast 
cancer patients and interestingly, the same trend was also 
observed in patients with Her2 amplification (Figure S1). 
These findings indicate an important role of ATG9A 
in breast cancer and highlight a potential link between 
ATG9A and Her2.
ATG9A overexpression reduces cell proliferation 
and increases apoptosis in trastuzumab 
resistance cells
Oncogenic signaling driven by Her2 is strongly 
associated with increased progression and poor prognosis. 
Previous studies have implicated Her2 expression and 
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Figure 1: SILAC analysis reveals ATG9A as a potential regulator of trastuzumab resistance. (A) Cell proliferation of 
BT474-TR and BT474 cells up to 5 days in the presence of increasing amounts of trastuzumab. (B) Experimental schematic outline of 
SILAC experiment. (C) Volcano scatter plot comparison of ratios for total proteins showing altered abundance in BT474 relative to BT474-
TR in the presence of trastuzumab (20 µg/ml). Significance threshold was calculated by a B Significance Test (Sig B). (D) SILAC Log2 
distribution of the significant B protein levels up or down regulated after SILAC analysis (E) Western blotting for ATG9A in BT474 and 
BT474-TR in the presence of trastuzumab (20 µg/ml). (F) Gene ontology terms in which ATG9A is classified. (G) SILAC data for the 
functional protein–protein interaction networks for Autophagy and Endosome GO terms. Protein nodes with red colour are up-regulated in 
BT474-TR, whereas green represents down-regulation in BT474-TR. Colour gradient indicates log2 ratio difference between BT474 and 
BT474-TR with lighter colour representing lower Log2 ratio and darker colour representing high Log2 ratio for each protein. Connective 
network lines thickness corresponds to the level of evidence of interaction. *P < 0.05 unpaired Student’s t test.
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down-stream signaling mediators as key regulators in 
cell proliferation and apoptosis [17, 18], prompt us to 
address whether ATG9A modulation could affect cellular 
proliferation. ATG9A overexpression in BT474-TR led 
to a significant decrease in cell proliferation as shown in 
Figure 2A (top graph), which was even more accentuated 
when trastuzumab was added to cells. Conversely, 
down-regulation of ATG9A by specific siRNA resulted 
in a significant increase in cell proliferation in BT474-
TR cells, whereas trastuzumab addition did not change 
cell proliferative response (Figure 2A; bottom graph). 
Moreover, parental BT474 did not show proliferative 
response to ATG9A overexpression (Figure 2B; (top 
graph) or inhibition by siRNA (Figure 2B; bottom graph) 
suggesting that ATG9A repressive effect is trastuzumab-
resistant specific. In support, JIMT1 and MDA-453 
cell lines, which are innately resistant to trastuzumab, 
showed a markedly decrease in proliferation upon 
ATG9A overexpression (Figure 2C–2D; top graph), 
which the opposite effects (increased proliferation) were 
observed after ATG9A knockdown (Figure 2C–2D; 
bottom graph). Next, we sought to investigate whether 
ATG9A inhibitory-proliferative effect could be due 
to cell cycle dysregulation. Our data showed that 
ATG9A overexpression resulted in an increase in subG1 
population without affecting other cell cycle phases, 
indicating an increase in apoptosis (Figure 2E). In support 
of this, caspase 3/7 levels were elevated upon ATG9A 
overexpression confirming the activation of apoptotic 
signaling (Figure 2F).
ATG9A decreases Her2 protein levels and 
supresses PI3K/AKT signaling
One of the well-established mechanism that 
impairs trastuzumab efficiency is the hyperactivation of 
the PI3K/ATK pathway [9], and AKT phosphorylation, 
a read-out for PI3K/AKT signaling, has been correlated 
with cell growth and survival [19]. We thus aimed to 
investigate whether the repressive proliferative effect 
on BT474-TR by ATG9A overexpression was through 
Her2 and its down-stream signaling mediators such as 
PI3K/AKT. Our data showed that Her2 protein basal 
levels were markedly decreased by ATG9A ectopic 
expression, an effect that was more accentuated with the 
addition of trastuzumab. Interestingly, this was observed 
in trastuzumab acquired resistant cells only (Figure 3A). 
In addition, AKT phosphorylation was also reduced 
in these cells indicating ATG9A’s ability to negatively 
regulate PI3K/AKT signaling possible via Her2 inhibition. 
Moreover, when ATG9A was down-regulated by specific 
RNA interference, Her2 total protein levels were markedly 
increased in BT474-TR cells but not in parental BT474 
cells. An increase in AKT phosphorylation was also 
proven to be specific for BT474-TR (Figure S2), as well 
as JIMT1 and MDA-453 cells (Figure S3). These findings 
indicate a specific role of ATG9A in regulating Her2 and 
downstream AKT signaling. 
To further evaluate whether the effect of ATG9A 
on Her2 basal protein level was a reflection of a 
transcriptional repression, we performed a quantitative 
real-time polymerase chain reaction (RT-qPCR). ATG9A 
overexpression did not affect the Her2 transcript levels in 
either parental BT474 or acquired trastuzumab resistant 
cells (BT474-TR) (Figure 3B). Interestingly, Her2 
regulated genes such as S100A4, HSF1, COX2 and IGFBP3 
were found to be modulated by ATG9A overexpression at 
different levels (Supplementary Figures S4, S5). Again, 
this effect was only observed in BT474-TR, JIMT1 and 
MDA-453 but not in BT474 cells, in accordance with what 
was previously observed on Her2 protein levels. Overall, 
these data indicate that ATG9A might directly regulate 
Her2 at protein level, subsequently resulting in a decrease 
of Her2 stability and its down-stream effectors. 
We then sought to elucidate whether ATG9A 
affects Her2 protein stability by blocking nascent protein 
translation with cyclohexamine (CHX). In BT474-TR, 
ATG9A overexpression triggered a decrease in Her2 
protein levels (Figure 3C) with a half-life reduction from 
t
1/2 
= 28.2 to t
1/2 
= 13.1. In BT474 cells, a marginal decrease 
was observed (Vector t
1/2 
= 38.01, ATG9A t
1/2 
= 32.5) in 
Her2 basal protein levels upon ATG9A overexpression 
(Figure 3C) indicating that its effect on Her2 stabilization 
is more significant in trastuzumab resistant cells. These 
results support the hypothesis of a repressive mechanism 
on ATG9A to maintain high levels of the tyrosine kinase 
receptor as an oncogenic driver and highlight that ATG9A 
decrease in BT474-TR might contribute to trastuzumab 
resistance. 
To confirm our findings in intrinsic trastuzumab 
resistant cells, we investigated whether ATG9A modulation 
would also affect Her2 protein and mRNA levels in 
JIMT1 and MDA-453 cells. Our data showed a significant 
decrease in Her2 protein and AKT phosphorylation in 
both JIMT1 and MDA-453 (Figure 3D). However, no 
change in Her2 mRNA levels was observed in both cell 
lines (Figure 3E). Upon CHX treatment, Her2 protein 
levels were more stable in control group comparing to 
ATG9A overexpression with a decrease of 40% and 27% 
in Her2 half-life protein levels for JIMT1 and MDA-453, 
respectively (Figure 3F).
ATG9A regulates Her2 degradation via c-Cbl 
ubiquitin ligase
A previous study indicated c-Cbl, an E3 ubiquitin 
ligase, as an important regulator of Her2 degradation 
[20]. Thus, we sought to investigate whether ATG9A 
modulates Her2 protein levels and degradation via c-Cbl. 
Immunoprecipitation assays showed that there was no 
direct interaction between ATG9A and c-Cbl in both 
BT474-TR and BT474 (Figure 4A). In addition, ATG9A 
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and Her2 are not binding partners in either cell line 
(Figure 4B). However, we observed an increase in c-Cbl 
capability to interact with Her2 upon ATG9A ectopic 
expression (Figure 4C), a phenomenon that was restricted 
to BT474-TR cells (Figure 4C–4D). Notably, targeting 
c-Cbl using siRNA significantly impaired ATG9A-induced 
degradation effect on Her2 protein levels and restored its 
abundance to basal conditions (Figure 4E). Likewise, 
PI3K/AKT signaling was also affected by c-Cbl targeted 
inhibition, an effect that appears to be trastuzumab 
independent, as no significant difference was observed 
in the presence or absence of the drug (Figure 4E). 
Figure 2: ATG9A overexpression represses cell proliferation and induces apoptosis in trastuzumab resistant cells. 
(A–D) Effect of ATG9A overexpression (top graphs) and siATG9A (bottom graphs) on cell proliferation in (A) BT474-TR, (B) BT474, (C) 
JIMT1 and (D) MDA-453 cells in the presence or absence of trastuzumab (20 µg/ml). (E) Cell cycle analysis of BT474-TR transfected with 
ATG9A or empty vector in the presence of trastuzumab for 24 h and 48 hours. (F) caspase3/7 levels of BT474-TR transfected with ATG9A 
or empty vector in the presence or absence of trastuzumab for 48 hours. The data presented are means ± SEM from three independent 
experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 unpaired Student’s t test.
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Figure 3: Her2 stability and protein levels are affected by ATG9A levels. (A) Protein abundance of ATG9A, Her2, AKT 
and P27/KIP upon transfection with ATG9A or empty vector in the presence or absence of trastuzumab (20 µg/ml) in BT474-TR and 
BT474 (B) mRNA expression levels for ATG9A and Her2 upon transfection with ATG9A or empty vector in the presence or absence 
of trastuzumab (20 µg/ml) in BT474-TR and BT474. (C) BT474-TR and BT474 cells were treated with Cyclohexamide (100 µM) for 
up to 48 hours after overexpression of ATG9A or empty vector in the presence or absence of trastuzumab (20 µg/ml). Half-life of Her2 
protein (t
1/2
) was calculated and compared between ATG9A and empty vector groups. (D) Protein abundance for ATG9A, Her2, AKT and 
(E) mRNA expression levels for ATG9A and Her2 in JIMT-1 and MDA-453 after transfection with ATG9A or empty vector in the presence 
or absence of trastuzumab (20 µg/ml). (F) JIMT1 and MDA-453 cells were treated with Cyclohexamide (100 µM) for up to 48 hours 
after overexpression of ATG9A or empty vector in the presence or absence of trastuzumab (20 µg/ml). Half-life of Her2 protein (t
1/2
) was 
calculated and compared between ATG9A and empty vector groups.
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In addition, ATG9A-induced inhibition of cell 
proliferation in BT474-TR was suppressed by c-Cbl 
down-regulation (Figure 4F), an effect that was not 
observed in BT474 cells (Figure 4F). Overall, these 
results suggest that ATG9A indirectly promotes the 
formation of c-Cbl/Her2 complex and enhances Her2 
degradation, consequently, affecting its downstream 
mediators such as PI3K/AKT. These effects of ATG9A 
seem to be mediated in a c-Cbl dependent manner.
c-Cbl induces K63 Her2 polyUb redirecting for 
endosome/lysosome targeted degradation
ATG9A affects Her2 degradation via c-Cbl and 
previous work demonstrated that the binding of c-Cbl 
to tyrosine 1112 (Y1112) of Her2 leads to ubiquitination 
[21]. Moreover, Her2 polyubiquitin linkages via lysine 63 
(K63) was associated with endosome trafficking to the 
lysosome leading to its degradation [22]. The ability of 
c-Cbl to induce K63 poly-ubiquitination (K63 polyUb) 
[23, 24] prompted us to investigate a potential role for 
ATG9A in affecting c-Cbl poly-ubiquitination of Her2 and 
lysosome targeted degradation. 
Our data showed that ATG9A ectopic expression 
in BT474-TR induced a significant increase of c-Cbl 
phosphorylation at tyrosine 774 (Y774) and a moderate 
increase at tyrosine 731 (Y731), two known sites 
involved in the regulation of c-Cbl protein degradation 
(Figure 5A). More importantly, Her2 phosphorylation on 
the tyrosine 1112 (Y1112) was significantly increased, 
confirming ATG9A’s ability to induce Her2 degradation 
via cbl activation (Figure 5A). We then sought to evaluate 
c-Cbl’s capability to induce K63 polyUb of Her2. Her2 
Immunoprecipitation in BT474-TR indicated an increase 
on K63 Her2 polyUb followed by ATG9A overexpression. 
This was abrogated by c-Cbl target inhibition by siRNA 
(Figure 5B), indicating a role for ATG9A in promoting 
Her2 degradation via c-Cbl induced K63 polyUb. 
Furthermore, we used two potent lysosome inhibitors 
(choroquine and bafilomycin) to examine whether ATG9A 
mediates Her2 lysosomal degradation. Both inhibitors 
were able to rescue ATG9A-induced Her2 degradation 
(Figure S6A).
In addition, MG132, a potent and selective inhibitor 
of the proteasome, failed to recover Her2 protein levels 
upon ATG9A overexpression (Figure S6B), reinforcing 
our hypothesis that ATG9A-induced Her2 degradation 
pathway is lysosome-dependent in trastuzumab resistant 
cells (BT474-TR). Despite the documented role of ATG9A 
in the phagosphore formation, there was no increase in 
autophagy influx as p62 and LC-3I/II protein levels were 
not affected by ectopic ATG9A expression (Figure S6C). 
The presence of Her2 within the lysosome was further 
confirmed by immunofluorescence, where LAMP1 
(a marker for lysosomes) showed a significant increase 
of co-localisation with Her2 in BT474-TR upon ectopic 
expression of ATG9A (Figure 5C). Moreover, to further 
confirm this finding, we used another known regulator 
of EFGR trafficking and marker for late endosomes, 
RAB7. Immunofluorescence staining showed elevated 
co-localisation between Her2 and RAB7 upon ATG9A 
overexpression (Figure S7). An increased co-localisation 
between LAMP1 with ATG9A was also observed 
in BT474-TR cells in comparison with BT474 cells 
(Figure 5D). Collectively, our results suggest a role for 
ATG9A in Her2 endosomal/lysosome target degradation 
via c-Cbl K63 polyUb, which might be a unique signature 
in trastuzumab resistant breast cancer cells. This in turn 
maintains the Her2 oncogenic signaling and tumorigenic 
potential.
DISCUSSION
Primary and acquired resistance to trastuzumab 
remains a major obstacle in the treatment of patients 
with Her2-amplified breast tumours [25]. It is therefore 
crucial to identify underlying mechanisms that could 
provide a more successful design of strategies to 
overcome this obstacle. Following this line of thought, 
we have used a pair of trastuzumab resistant cell line 
that was established by gradual exposure to trastuzumab 
(BT474-TR) and its parental BT474 as models in this 
study (Figure 1A). This model is close to the clinical 
setting where acquired resistance is mainly observed after 
prolonged administration of trastuzumab. Using SILAC-
based quantitative proteomics, we compared the global 
proteomic profile of BT474-TR and parental BT474 
cells to identify potential targets that are implicated in 
trastuzumab resistance development in BCa. We found 
that ATG9A was one of the most significantly down-
regulated proteins in BT474-TR cells compared to 
sensitive parental BT474 (Figure 1C, 1E). As previous 
evidence suggests that ATG9A is involved in formation of 
the integral membrane during phagophore formation [40], 
it was reasonable to propose an autophagy promoting role 
for ATG9A. However, our data showed that ATG9A levels 
were down-regulated in trastuzumab resistance cells, 
whereas protein expression levels of autophagy markers 
such as SQSTM1/p62 indicated elevated autophagy flux 
(Figure 1G), which is in accordance with previous studies 
where autophagy influx was shown to be increased in 
trastuzumab resistance cells [13, 15]. It is possible that 
ATG9A might act as a negative regulator of autophagy in 
trastuzumab resistant cells only, but thus far we have no 
evidence supporting this.
On the other hand, our results uncovered an 
interesting role of ATG9A in contributing to trastuzumab 
resistance in BCa. First of all, overexpression of ATG9A 
was sufficient to decrease proliferation in both acquired 
resistant and naturally resistant cells (Figure 2A–2D), 
and the addition of trastuzumab had no significant 
repressive effect but did reduce Her2 levels to a further 
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Figure 4: ATG9A induces Her2 protein degradation via c-Cbl E3 ubiquitin ligase. (A) Immunoprecipitation of ATG9A 
and (B) Her2 followed by western blotting of indicated antibodies in BT474-TR and BT474 cells. IgG antibodies were used as controls. 
(C) Immunoprecipitation of Her2 in BT474-TR and (D) BT474 cells transfected with vector and ATG9A-encoding plasmid in the presence 
of trastuzumab (20 µg/ml) for 48 hours, followed by western blotting of indicated antibodies. (E) Western blotting for Her2, ATG9A, 
pAKT and c-Cbl upon sic-Cbl with or without ATG9A overexpression in the presence or absence of trastuzumab (20 µg/ml) in BT474-TR. 
Protein levels were analysed and quantified using Image J software. Her2 bands were normalised to α-tubulin. (F) BT474 and BT474-TR 
cell proliferation was analysed after siRNA silencing against c-Cbl (or a non-targeting siRNA (siCTL)), followed by overexpression of 
ATG9A (or control vector).
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Figure 5: c-Cbl induces K63 Her2 polyUb redirecting for lysosomal targeted degradation. (A) Effect of ATG9A on 
phosphorylation of c-Cbl in BT474-TR. Cells were transfected with vector and ATG9A-encoding plasmid in the presence of trastuzumab 
(20 µg/ml). Protein levels for ATG9A, c-Cbl total and phosphorylation sites Tyr 731 and 774, Her2 total and phosphorylated Tyr 1112 
were quantified by Image J software. Bands were normalised to α-tubulin. (B) Immunoprecipitation of Her2 followed by western blotting 
for K63 and Her2 in BT474-TR cells transfected with siRNA against c-Cbl or siRNA, upon overexpressing ATG9A or control vector. IgG 
was used as control. (C) Immunofluorescence staining for LAMP1 and Her2 in BT474-TR cells upon transfection with vector or ATG9A-
encoding plasmid in the presence of trastuzumab (20 µg/ml). Percentage of Her2/LAMP1 co-localisation was quantified using LEICA LAS 
AF lite software. (D) Immunofluorescence staining for GFP-ATG9A and LAMP1 in BT474 and BT474-TR transfected with ATG9A-GFP 
encoding plasmid in the presence of trastuzmab (20 µg/ml). Data is representative of three experiments. *P < 0.05, unpaired Student’s t test.
Oncotarget27608www.impactjournals.com/oncotarget
extend in acquired resistant cells (Figure 2A). Secondly, 
Her2 overexpression and hyperactivation of PI3K/
AKT pathway has been correlated with trastuzumab 
resistance [18, 27, 28]. Here we showed that ATG9A 
was able to affect Her2-AKT driven signaling leading 
to a reduction in cell proliferation and an increase in 
apoptosis (Figure 1F). 
More importantly, we revealed for the first time 
that ATG9A might act through c-Cbl to induce Her2 
degradation in trastuzumab resistant cells but not 
sensitive cells. Our data demonstrated that ATG9A 
overexpression increased c-Cbl-Her2 interaction resulting 
in Her2 receptor degradation, an effect that appears to be 
independent of ATG9A and c-Cbl association (Figure 
4B). We were also not able to detect any direct interaction 
between ATG9A and Her2 suggesting the existence of an 
unidentified mediator responsible for ATG9A-induced 
c-Cbl activation. 
Previous studies showed that Y1112 is a docking 
site for Her2 ubiquitination by c-Cbl, an effect mediated 
by trastuzumab leading to receptor internalisation and 
consequent degradation [20]. In addition, c-Cbl is able 
to produce either K48 or K63 ubiquitin chains for Her2 
polyubiquitin editing, resulting in proteasome or lysome 
dependent degradation [22]. In line with these findings, 
we observed that ATG9A overexpression markedly 
increased T1112 phosphorylation (Figure 5A) and K63 
polyUb (Figure 5B) of Her2. Moreover, ATG9A was able 
to decrease Her2 half-life (Figure 3C) and to increase co-
localisation between Her2 with RAB-7 and LAMP-1, two 
markers for endosome/lysosome trafficking, highlighting a 
new role for ATG9A in c-Cbl-induced degradation of Her2 
via lysosomal degradation.
Taken together, our results uncovered a unique 
role of ATG9A in trastuzumab resistance (Figure 6) and 
highlight the clinical relevance of ATG9A as a target 
in patients where Her2 targeting drugs are no longer 
effective. However, as this is the first study to establish 
a new function of ATG9A involvement in trastuzumab 
resistance development, further work and in vivo studies, 
including use of patient derived xenograft (PDX) models 
might help us to better understand its behaviour and 
to validate whether it is an effective target in mice. 
Future work is also required in order to elucidate the 
exact mechanism of action of ATG9A-mediated Cbl’s 
activation and its subsequent ability to promote the 
degradation of Her2. Additional questions include why 
this effect is observed only in trastuzumab resistant cells, 
and more importantly, whether this is the case in patients’ 
tissues as well. 
Figure 6: Schematic model of ATG9A’s role in trastuzumab resistant cells. ATG9A promotes c-Cbl recruitment to the receptor 
kinase Her2 on T1112, a known c-Cbl docking site, leading to an increase in Her2 poly-ubiquitination. This ultimately results in a decrease 
in Her2 protein levels, Her2 transcriptional activity and Her2 downstream PI3K/AKT signaling.
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MATERIALS AND METHODS
Cell lines, reagents, antibodies and plasmids
BT474, JIMT1 and MDA-453 cells were 
maintained in Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% fetal calf serum 
(FCS) and 1% penicillin (P)/streptomycin (S)/glutamine 
(G). BT474 trastuzumab-resistant (BT474-TR) cells 
were generated by treating parental BT474 cells with 
increasing concentrations of trastuzumab for 6 months, 
as described previously [29]. BT474-TR cells were 
normally maintained in the presence of trastuzumab (10 
ug/ml). All cells were incubated at 37°C in humidified 
5% CO2. FuGENE
® HD transfection reagent was 
obtained from Roche (Burgess Hill, UK). Plasmids 
containing human wild type ATG9A and empty vector 
were obtained from OriGene. siRNAs targeting 
ATG9A (#1: CTGGATCCACCGGCTTATCAA; #2: 
CACCCGTGGTCTCAAGTACAA) were from Qiagen. 
Cells were transfected with either siControl or verified 
siRNAs against the targets (final concentration 40 nM) 
and HiPerFect reagent according to the manufacturer’s 
instructions (Qiagen) for 72 hours.
Antibodies used : ATG9A (ab108338, Abcam), Her2 
(#2165, Cell Signaling Technology), α-tubulin (ab4074, 
Abcam), Phospho-Akt (Ser473) (#9271, Cell Signaling 
Technology), Akt (#9272, Cell Signaling Technology), 
c-Cbl (#2747, Cell Signaling Technology), Phospho-c-Cbl 
(Tyr731) (#3554, Cell Signaling Technology), Phospho-
c-Cbl (Tyr774) (#3555, Cell Signaling Technology), 
LAMP1 (ab24170, Abcam).
SILAC cell culture
To generate SILAC conditions (Dundee Cell 
Products Ltd, Dundee, UK), normal DMEM medium 
deficient in arginine (R) and lysine (K) was supplemented 
with stable isotope-encoded arginine and lysine as 
previously described [30–32]. L-[13C
6
] arginine (R6)/L-
[2H
4
] lysine (K4) and L-[13C
6
, 15N
4
] arginine (R10)/L-
[13C
6
, 15N2] lysine (K8) were used for ‘medium’ and 
‘heavy’ labelling respectively. Parental BT474 and BT474 
Trastuzumab resistant (BT474-TR) cells were then grown 
for 7 cell divisions in either R6K4 ‘medium’ or R10K8 
‘heavy’ medium, respectively, supplemented with 10% 
dialyzed fetal bovine serum (10 kDa MWCO), 1% 
(10 mg/ml) streptomycin/(10,000 units/ml) penicillin, 
2 mM glutamine and 1 mM sodium pyruvate. 
Protein digestion and peptide fractionation
Equal amounts of protein from labelled samples 
(1:1) were combined prior to protein digestion. Briefly, 
samples were reduced in 10 mM DTT and alkylated in 
50 mM Iodoacetamide prior to boiling in loading buffer, 
and then separated by one-dimensional SDS-PAGE 
(4–12% Bis-Tris Novex mini-gel, Invitrogen) and 
visualized by colloidal Coomassie staining (Novex, 
Invitrogen). The entire protein gel lanes were excised 
and cut into 10 slices each. Every gel slice was subjected 
to in-gel digestion with trypsin overnight at 37°C. The 
resulting tryptic peptides were extracted by formic acid 
(1%) and acetonitrile (CH
3
CN), lyophilized in a speedvac 
and resuspended in 1% formic acid.
Mass spectrometry analysis
As described previously [32], trypsin-digested 
peptides were separated using an Ultimate 3000 RSLC 
(Thermo Scientific) nanoflow LC system. On average 
0.5 µg was loaded with a constant flow of 5 µl/min onto 
an Acclaim PepMap100 nanoViper C18 trap column 
(100 µm inner-diameter, 2 cm; Themro Scientific). After 
trap enrichment, peptides were eluted onto an Acclaim 
PepMap RSLC nanoViper, C18 column (75 µm, 15 cm; 
Thermo Scientific) with a linear gradient of 2–40% solvent 
B (80% acetonitrile with 0.08% formic acid) over 65 min 
with a constant flow of 300 nl/min. The HPLC system 
was coupled to a linear ion trap Orbitrap hybrid mass 
spectrometer (LTQ-Orbitrap Velos, Thermo Scientific) 
via a nano electrospray ion source (Thermo Scientific). 
The spray voltage was set to 1.2 kV, and the temperature 
of the heated capillary was set to 250°C. Full-scan MS 
survey spectra (m/z 335–1800) in profile mode were 
acquired in the Orbitrap with a resolution of 60,000 after 
accumulation of 1,000,000 ions. The fifteen most intense 
peptide ions from the preview scan in the Orbitrap were 
fragmented by collision-induced dissociation (normalized 
collision energy, 35%; activation Q, 0.250; and activation 
time, 10 ms) in the LTQ Orbitrap after the accumulation 
of 10,000 ions. Maximal filling times were 1,000 ms for 
the full scans and 150 ms for the MS/MS scans. Precursor 
ion charge state screening was enabled, and all unassigned 
charge states as well as singly charged species were 
rejected. The dynamic exclusion list was restricted to a 
maximum of 500 entries with a maximum retention period 
of 180 seconds and a relative mass window of 15 ppm. 
The lock mass option was enabled for survey scans to 
improve mass accuracy [33]. Data were acquired using 
the Xcalibur software.
Proteome quantification 
The raw mass spectrometric data files obtained for 
each experiment were collated into a single quantitated 
data set using MaxQuant [34] and the Andromeda search 
engine software [35]. Peptide ratios were calculated for 
each arginine- and/or lysine-containing peptide as the 
peak area of labelled arginine/lysine divided by the peak 
area of non-labelled arginine/lysine for each single-
scan mass spectrum. Peptide ratios for all arginine- and 
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lysine-containing peptides sequenced for each protein 
were averaged. Data were normalised using 1/median ratio 
value for each identified protein group per labelled sample. 
RNA extraction and RT-qPCR
RNeasy kit (Qiagen) was used to isolate total RNA. 
Reverse transcription was performed using high capacity 
cDNA reverse transcription kit (Applied Biosystems). RT-
qPCR analysis was performed on a 7900HT Thermocycler 
(Applied Biosystems) using SYBR® Green master mix and 
certified primers for ATG9A, HER2 and GAPDH from 
QuantiTect Primer Assay, Qiagen.
Cell proliferation assay
Sulphorhodamine B (SRB) assay was performed to 
determine the growth of breast cancer cell lines in 96-well 
plates. Briefly, after different treatments, cells were fixed 
by adding 100 µl/well of ice-cold 40% trichloroacetic acid 
(TCA) to each culture for 1 h in cold room. Plates were 
then washed 5× times in running tap water. Cells were 
stained with 100 µl of 0.4% (W/V) SRB (Sigma S-9012) 
in 1% acetic acid for 30 mins and plates were washed 
5 times in 1% acetic acid and left to air dry overnight. 
On the day of reading plates, bound dye was solubilized 
by adding 100 µl of 10 mM tris base (pH 10.5) to all the 
wells. The absorbance (560–580 nm) was measured on a 
Tecan microplate reader.
Western blotting
Protein lysates were extracted using RIPA buffer 
(Sigma) including fresh protease and phosphatase 
inhibitors and standard western blotting protocol was 
performed as described before [31]. 
Immunoprecipitation assay
Cells were seeded and transfected with indicated 
constructs including empty vector (pCMV6) or ATG9A 
(pCMV6-ATG9A) using FuGENE® HD. Cells were lysed 
and total protein was quantified. IgG or anti-Her2 antibody 
was pre-incubated with beads for 2 hours to form IP matrix 
complex (ImmunoCruz™ IP/WB Optima B System, Santa 
Cruz). 2 mg protein lysate was added into the beads and was 
incubated on a rotator overnight at 4°C. Beads were then 
washed with RIPA buffer for three times and were heated 
in SDS loading buffer. Western blotting was performed to 
detect protein levels using indicated antibodies.
Immunofluorescence staining
Cells seeded on glass coverslips and fixed in 4% 
w/v paraformaldehyde at 37°C for 15 min, permeabilized 
with 0.1% Triton-X for 10 min and incubated in 
immuno-fluorescent blocking buffer (10% AB-serum 
in PBS) for 1 h, followed by incubation with specific 
primary antibodies (LAMP1 (1:100) and Her2 (1:50)). 
After washing with PBS, coverslips were incubated 
for 45 min at 37°C with indicated anti-mouse/rabbit-
IgG Alexa Fluor® antibodies (Invitrogen). Nuclei were 
visualized by DAPI staining. Cells were examined on 
an Axiovert-200 laser scanning inverted microscope 
(Zeiss) equipped with a confocal imaging system. Image 
composites of ~20 × 0.5 μm z-stacks were obtained 
using Axiovision LE software (Zeiss) as previously 
described [36]. 
FACS analysis
Cells were transfected with empty vector or full-
length ATG9A plasmids for 24 hours and collected, 
washed 3× times in ice-cold PBS, fixed in 70% ethanol 
at 4°C, and then stained with 50 μg/ml propidium 
iodide. Cells were analyzed on a LSR II flow cytometer 
(BD Biosciences) using the FACSDiva 6.0 software 
(BD Biosciences).
Kaplan-Meier (KM) plotter analysis
KM Plotter online survival analysis, which has 
massive gene expression data and survival information of 
more than 3,000 patients, was used [16]. Gene expression 
data and relapse free and overall survival information are 
publically available from the Gene Expression Omnibus 
(GEO, http:// www.ncbi.nlm.nih.gov/geo/) and The Cancer 
Genome Atlas (TCGA). The expression levels of ATG9A 
were selected. The relevance on relapse free survival 
(RFS) in all types of breast cancer and Her2 amplified was 
assessed.
Bioinformatics and statistical analyses
The bioinformatic analyses for identifying top hits 
from SILAC-quantitative proteomics were performed 
in R [37] and SWI-Prolog [38], using Real [39] for 
connecting the two systems. Significance B test was 
performed to characterize the most significantly regulated 
proteins between BT474 parental and BT474-TR cells 
(p < 0.05) [34]. For functional networking, GO analysis 
was performed at the level 2 of the three GO domains: 
biological process (BP) cellular component (CC) and 
molecular function (MF) [40]. Furthermore, the hyper-
geometric test from GOstats package was used to identify 
GO terms that are enriched in each cell line [41]. For 
every overrepresented GO term, a network connecting 
de-regulated genes in this GO term was drawn showing 
the networks amongst these genes in the STRING 
protein-protein interactions database [42]. Only edges 
with a confidence value greater than 500 were included 
(range: 0–999). 
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